The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.